Have a feature idea you'd love to see implemented?
Let us know!
ANIX Anixa Biosciences Inc
Price (delayed)
$2.69
Market cap
$86.56M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.39
Enterprise value
$85.57M
Anixa Biosciences Inc. is a biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type
Highlights
The company's revenue has shrunk by 100% YoY
The gross profit has dropped by 100% year-on-year
Key stats
What are the main financial stats of ANIX
Market
Valuations
Earnings
Shares outstanding
32.18M
Market cap
$86.56M
Enterprise value
$85.57M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.95
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$12.36M
EBIT
-$12.36M
EBITDA
-$12.32M
Free cash flow
-$8.38M
Per share
Balance sheet
Liquidity
EPS
-$0.39
EPS diluted
-$0.39
Free cash flow per share
-$0.26
Book value per share
$0.68
Revenue per share
$0
TBVPS
$0.71
Total assets
$22.91M
Total liabilities
$2.22M
Debt
$237,000
Equity
$21.77M
Working capital
$20.67M
Debt to equity
0.01
Current ratio
11.31
Quick ratio
10.56
Net debt/EBITDA
0.08
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-50.4%
Return on equity
-52.4%
Return on invested capital
-56.6%
Return on capital employed
-59.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ANIX stock price
How has the Anixa Biosciences stock price performed over time
Intraday
0%
1 week
-5.61%
1 month
-11.66%
1 year
-28.84%
YTD
-30.67%
QTD
-14.6%
Financial performance
How have Anixa Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$13.72M
Net income
-$12.36M
Gross margin
N/A
Net margin
N/A
The company's revenue has shrunk by 100% YoY
The gross profit has dropped by 100% year-on-year
ANIX's operating income is down by 19% year-on-year and by 6% since the previous quarter
The net income has declined by 17% year-on-year and by 7% since the previous quarter
Growth
What is Anixa Biosciences's growth rate over time
Valuation
What is Anixa Biosciences stock price valuation
P/E
N/A
P/B
3.95
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ANIX's EPS is down by 11% year-on-year and by 5% since the previous quarter
The price to book (P/B) is 25% lower than the 5-year quarterly average of 5.3 and 16% lower than the last 4 quarters average of 4.7
The equity has contracted by 15% YoY and by 8% from the previous quarter
The company's revenue has shrunk by 100% YoY
Efficiency
How efficient is Anixa Biosciences business performance
The return on equity has declined by 35% year-on-year and by 11% since the previous quarter
The company's return on assets fell by 34% YoY and by 11% QoQ
Anixa Biosciences's return on invested capital has decreased by 9% QoQ
Dividends
What is ANIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ANIX.
Financial health
How did Anixa Biosciences financials performed over time
ANIX's total liabilities is up by 25% QoQ and by 11% YoY
The company's quick ratio fell by 24% QoQ and by 24% YoY
The debt is 99% less than the equity
The debt has soared by 59% from the previous quarter and by 27% YoY
The equity has contracted by 15% YoY and by 8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.